Telomeres and telomerase in oncogenesis (Review)
- Authors:
- Tomasz Trybek
- Artur Kowalik
- Stanisław Góźdź
- Aldona Kowalska
-
Affiliations: Endocrinology Clinic, Holycross Cancer Center, 25‑734 Kielce, Poland, Department of Molecular Diagnostics, Holycross Cancer Center, 25‑734 Kielce, Poland, The Faculty of Health Sciences, Jan Kochanowski University, 25‑319 Kielce, Poland - Published online on: May 21, 2020 https://doi.org/10.3892/ol.2020.11659
- Pages: 1015-1027
-
Copyright: © Trybek et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Seluanov A, Gladyshev VN, Vijg J and Gorbunova V: Mechanisms of cancer resistance in long-lived mammals. Nat Rev Cancer. 18:433–441. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shay JW and Wright WE: Telomeres and telomerase: Three decades of progress. Nat Rev Genet. 20:299–309. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu T, Yuan X and Xu D: Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: Biological and clinical implications. Genes (Basel). 7(pii): E382016. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan X, Larsson C and Xu D: Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: Old actors and new players. Oncogene. 38:6172–6183. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dilley RL and Greenberg RA: ALTernative telomere maintenance and cancer. Trends Cancer. 1:145–156. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hayflick L: The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 37:614–636. 1965. View Article : Google Scholar : PubMed/NCBI | |
|
Olovnikov AM: A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 41:181–190. 1973. View Article : Google Scholar : PubMed/NCBI | |
|
Szostak JW and Blackburn EH: Cloning yeast telomeres on linear plasmid vectors. Cell. 29:245–255. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Blackburn EH: Structure and function of telomeres. Nature. 350:569–573. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Greider CW: Telomerase is processive. Mol Cell Biol. 11:4572–4580. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL and Wu JR: A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA. 85:6622–6626. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Makarov VL, Hirose Y and Langmore JP: Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell. 88:657–666. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Wellinger RJ and Sen D: The DNA structures at the ends of eukaryotic chromosomes. Eur J Cancer. 33:735–749. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Blackburn EH: Switching and signaling at the telomere. Cell. 106:661–673. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Greider CW and Blackburn EH: A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature. 337:331–337. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Lendvay TS, Morris DK, Sah J, Balasubramanian B and Lundblad V: Senescence mutants of Saccharomyces cerevisiae with a defect in telomere replication identify three additional EST genes. Genetics. 144:1399–1412. 1996.PubMed/NCBI | |
|
Lingner J and Cech TR: Purification of telomerase from Euplotes aediculatus: Requirement of a primer 3′ overhang. Proc Natl Acad Sci USA. 93:10712–10717. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Lai S, Andrews LG and Tollefsbol TO: Genetic and epigenetic modulation of telomerase activity in development and disease. Gene. 340:1–10. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer. 33:787–791. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al: TERT promoter mutations in familial and sporadic melanoma. Science. 339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L and Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science. 339:957–959. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmermann M, Kibe T, Kabir S and de Lange T: TRF1 negotiates TTAGGG repeat-associated replication problems by recruiting the BLM helicase and the TPP1/POT1 repressor of ATR signaling. Genes Dev. 28:2477–2491. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Arnoult N and Karlseder J: Complex interactions between the DNA-damage response and mammalian telomeres. Nat Struct Mol Biol. 22:859–866. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Denchi EL and de Lange T: Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature. 448:1068–1071. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Janoušková E, Nečasová I, Pavloušková J, Zimmermann M, Hluchý M, Marini V, Nováková M and Hofr C: Human Rap1 modulates TRF2 attraction to telomeric DNA. Nucleic Acids Res. 43:2691–2700. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Frescas D and de Lange T: TRF2-tethered TIN2 can mediate telomere protection by TPP1/POT1. Mol Cell Biol. 34:1349–1362. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Stewart JA, Chaiken MF, Wang F and Price CM: Maintaining the end: Roles of telomere proteins in end-protection, telomere replication and length regulation. Mutat Res. 730:12–19. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Martínez P and Blasco MA: Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer. 11:161–176. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kowalska A and Kowalik A: Telomeres and telomerase in oncogenesis. Contemp Oncol (Pozn). 10:485–496. 2006. | |
|
Shore D and Bianchi A: Telomere length regulation: Coupling DNA end processing to feedback regulation of telomerase. EMBO J. 28:2309–2322. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bourgeron T, Xu Z, Doumic M and Teixeira MT: The asymmetry of telomere replication contributes to replicative senescence heterogeneity. Sci Rep. 5:153262015. View Article : Google Scholar : PubMed/NCBI | |
|
Hemann MT, Strong MA, Hao LY and Greider CW: The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 107:67–77. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Pedram M, Sprung CN, Gao Q, Lo AWI, Reynolds GE and Murnane JP: Telomere position effect and silencing of transgenes near telomeres in the mouse. Mol Cell Biol. 26:1865–1878. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Robin JD, Ludlow AT, Batten K, Magdinier F, Stadler G, Wagner KR, Shay JW and Wright WE: Telomere position effect: Regulation of gene expression with progressive telomere shortening over long distances. Genes Dev. 28:2464–2476. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jafri MA, Ansari SA, Alqahtani MH and Shay JW: Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 8:692016. View Article : Google Scholar : PubMed/NCBI | |
|
Kyo S, Takakura M, Fujiwara T and Inoue M: Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 99:1528–1538. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kang SS, Kwon T, Kwon DY and Do SI: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem. 274:13085–13090. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Broccoli D, Young JW and de Lange T: Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA. 92:9082–9086. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Härle-Bachor C and Boukamp P: Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA. 93:6476–6481. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Kyo S, Takakura M, Kohama T and Inoue M: Telomerase activity in human endometrium. Cancer Res. 57:610–614. 1997.PubMed/NCBI | |
|
Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishioka S and Yamakido M: Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol. 155:3711–3715. 1995.PubMed/NCBI | |
|
Ramirez RD, Wright WE, Shay JW and Taylor RS: Telomerase activity concentrates in the mitotically active segments of human hair follicles. J Invest Dermatol. 108:113–117. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Cesare AJ and Reddel RR: Alternative lengthening of telomeres: Models, mechanisms and implications. Nat Rev Genet. 11:319–330. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, et al: Altered telomeres in tumors with ATRX and DAXX mutations. Science. 333:4252011. View Article : Google Scholar : PubMed/NCBI | |
|
Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, et al: A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res. 11:217–225. 2005.PubMed/NCBI | |
|
Im E, Yoon JB, Lee HW and Chung KC: Human telomerase reverse transcriptase (hTERT) positively regulates 26s proteasome activity. J Cell Physiol. 232:2083–2093. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hu C, Ni Z, Li BS, Yong X, Yang X, Zhang JW, Zhang D, Qin Y, Jie MM, Dong H, et al: hTERT promotes the invasion of gastric cancer cells by enhancing FOXO3a ubiquitination and subsequent ITGB1 upregulation. Gut. 66:31–42. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Saretzki G: Extra-telomeric functions of human telomerase: Cancer, mitochondria and oxidative stress. Curr Pharm Des. 20:6386–6403. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, Ganesan S, Lansdorp PM, Collins K and Hahn WC: The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci USA. 102:8222–8227. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Li Q, Li K, Chen L, Li W, Hou M, Liu T, Yang J, Lindvall C, Björkholm M, et al: Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 32:4203–4213. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang K, Guo Y, Wang X, Zhao H, Ji Z, Cheng C, Li L, Fang Y, Xu D, Zhu HH and Gao WQ: WNT/β-catenin directs self-renewal symmetric cell division of hTERThigh prostate cancer stem cells. Cancer Res. 77:2534–2547. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ding D, Xi P, Zhou J, Wang M and Cong YS: Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-κB-dependent transcription. FASEB J. 27:4375–4383. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lassmann T, Maida Y, Tomaru Y, Yasukawa M, Ando Y, Kojima M, Kasim V, Simon C, Daub CO, Carninci P, et al: Telomerase reverse transcriptase regulates microRNAs. Int J Mol Sci. 16:1192–1208. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Drevytska TI, Nagibin VS, Gurianova VL, Kedlyan VR, Moibenko AA and Dosenko VE: Silencing of TERT decreases levels of miR-1, miR-21, miR-29a and miR-208a in cardiomyocytes. Cell Biochem Funct. 32:565–570. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX, Li Y, Franzoso G, Li S, Guccione E and Tergaonkar V: Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J Clin Invest. 125:2109–2122. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mattiussi M, Tilman G, Lenglez S and Decottignies A: Human telomerase represses ROS-dependent cellular responses to tumor necrosis factor-α without affecting NF-κB activation. Cell Signal. 24:708–717. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, Wong M, Zhang Z, Li G, Sung WK, et al: Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol. 14:1270–1281. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Toh L, Lau P and Wang X: Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer. J Biol Chem. 287:32494–32511. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cong YS, Wen J and Bacchetti S: The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter. Hum Mol Genet. 8:137–142. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, et al: DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J Clin Invest. 129:223–229. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Casillas MA, Brotherton SL, Andrews LG, Ruppert JM and Tollefsbol TO: Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene. 316:57–65. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bellon M and Nicot C: Regulation of telomerase and telomeres: Human tumor viruses take control. J Natl Cancer Inst. 100:98–108. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q, et al: Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 49:349–357. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K and Kumar R: TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA. 110:17426–17431. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang K, Liu T, Liu L, Liu J, Liu C, Wang C, Ge N, Ren H, Yan K, Hu S, et al: TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget. 5:1829–1836. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cevik D, Yildiz G and Ozturk M: Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol. 21:311–317. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N, Alldinger I, Schmitt T, Egerer G, Penzel R, et al: TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res. 33:332014. View Article : Google Scholar : PubMed/NCBI | |
|
Vinagre J, Pinto V, Celestino R, Reis M, Pópulo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM, et al: Telomerase promoter mutations in cancer: An emerging molecular biomarker? Virchows Arch. 465:119–133. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bell RJA, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, et al: Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 348:1036–1039. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Kost J, Sulovari A, Wong N, Liang WS, Cao J and Li D: A virome-wide clonal integration analysis platform for discovering cancer viral etiology. Genome Res. 29:819–830. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Strååt K, Liu C, Rahbar A, Zhu Q, Liu L, Wolmer-Solberg N, Lou F, Liu Z, Shen J, Jia J, et al: Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst. 101:488–497. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, von Felden J, Martins-Filho SN, Sia D, Stueck A, Ward SC and Fiel MI: A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene. 37:3740–3752. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hurst CD, Platt FM and Knowles MA: Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol. 65:367–369. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Juratli TA, Stasik S, Zolal A, Schuster C, Richter S, Daubner D, Juratli MA, Thowe R, Hennig S, Makina M, et al: TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas: A pilot prospective study. Clin Cancer Res. 24:5282–5291. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Liu C, Fotouhi O, Fan Y, Wang K, Xia C, Shi B, Zhang G, Wang K, Kong F, et al: TERT promoter hypermethylation in gastrointestinal cancer: A potential stool biomarker. Oncologist. 22:1178–1188. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bougel S, Lhermitte B, Gallagher G, de Flaugergues JC, Janzer RC and Benhattar J: Methylation of the hTERT promoter: A novel cancer biomarker for leptomeningeal metastasis detection in cerebrospinal fluids. Clin Cancer Res. 19:2216–2223. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bianchi F, Nicassio F, Marzi M, Belloni E, Dall'olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G and Di Fiore PP: A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 3:495–503. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nagore E, Heidenreich B, Rachakonda S, Garcia-Casado Z, Requena C, Soriano V, Frank C, Traves V, Quecedo E, Sanjuan-Gimenez J, et al: TERT promoter mutations in melanoma survival. Int J Cancer. 139:75–84. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan Y, Qi C, Maling G, Xiang W, Yanhui L, Ruofei L, Yunhe M, Jiewen L and Qing M: TERT mutation in glioma: Frequency, prognosis and risk. J Clin Neurosci. 26:57–62. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, et al: TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 99:E754–765. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R and Xing M: TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 23:R143–R155. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D, Merino D, et al: Methylation of the TERT promoter and risk stratification of childhood brain tumours: An integrative genomic and molecular study. Lancet Oncol. 14:534–542. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Svahn F, Paulsson JO, Stenman A, Fotouhi O, Mu N, Murtha TD, Korah R, Carling T, Bäckdahl M, Wang N, et al: TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma. Int J Mol Med. 42:1675–1683. 2018.PubMed/NCBI | |
|
Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, et al: TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 99:E1130–E1136. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Macerola E, Loggini B, Giannini R, Garavello G, Giordano M, Proietti A, Niccoli C, Basolo F and Fontanini G: Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch. 467:177–184. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Zhang T, Zhu G and Xing M: Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun. 9:5792018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Yin Y, Wang J, Shi B, Zhang L, Qian D, Li C, Zhang H, Wang S, Zhu J, et al: Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC. Oncotarget. 8:179–190. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ and De Marzo AM: Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res. 62:6405–6409. 2002.PubMed/NCBI | |
|
Pestana A, Vinagre J, Sobrinho-Simões M and Soares P: TERT biology and function in cancer: Beyond immortalisation. J Mol Endocrinol. 58:R129–R146. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Frink RE, Peyton M, Schiller JH, Gazdar AF, Shay JW and Minna JD: Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. Oncotarget. 7:31639–31651. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, et al: A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann Oncol. 26:354–362. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Burchett KM, Yan Y and Ouellette MM: Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS One. 9:e851552014. View Article : Google Scholar : PubMed/NCBI | |
|
Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, et al: Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 22:1410–1418. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, Wright WE and Shay JW: In vivo inhibition of lung cancer by GRN163L: A novel human telomerase inhibitor. Cancer Res. 65:7866–7873. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tokcaer-Keskin Z, Dikmen ZG, Ayaloglu-Butun F, Gultekin S, Gryaznov SM and Akcali KC: The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6. Stem Cell Rev Rep. 6:224–233. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Burchett KM, Etekpo A, Batra SK, Yan Y and Ouellette MM: Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells. Oncotarget. 8:83754–83767. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Koziel JE and Herbert BS: The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells. Breast Cancer Res Treat. 149:607–618. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Zhang J, Yang S, Kuang Z, Tan G, Yang G, Wei Q and Guo Z: Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. Oncotarget. 8:13600–13619. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chhabra G, Wojdyla L, Frakes M, Schrank Z, Leviskas B, Ivancich M, Vinay P, Ganapathy R, Ramirez BE and Puri N: Mechanism of action of G-quadruplex-forming oligonucleotide homologous to the telomere overhang in melanoma. J Invest Dermatol. 138:903–910. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Schrank Z, Khan N, Osude C, Singh S, Miller RJ, Merrick C, Mabel A, Kuckovic A and Puri N: Oligonucleotides targeting telomeres and telomerase in cancer. Molecules. 23(pii): E22672018. View Article : Google Scholar : PubMed/NCBI | |
|
Pitman RT, Wojdyla L and Puri N: Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma. Oncotarget. 4:761–771. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Puri N, Pitman RT, Mulnix RE, Erickson T, Iness AN, Vitali C, Zhao Y and Salgia R: Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 343:14–23. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wojdyla L, Stone AL, Sethakorn N, Uppada SB, Devito JT, Bissonnette M and Puri N: T-oligo as an anticancer agent in colorectal cancer. Biochem Biophys Res Commun. 446:596–601. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Weng D, Cunin MC, Song B, Price BD, Eller MS, Gilchrest BA, Calderwood SK and Gong J: Radiosensitization of mammary carcinoma cells by telomere homolog oligonucleotide pretreatment. Breast Cancer Res. 12:R712010. View Article : Google Scholar : PubMed/NCBI | |
|
Guzman H, Sanders K, Idica A, Bochnakian A, Jury D, Daugaard I, Zisoulis DG and Pedersen IM: miR-128 inhibits telomerase activity by targeting TERT mRNA. Oncotarget. 9:13244–13253. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou N, Fei D, Zong S, Zhang M and Yue Y: MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer. Oncol Lett. 12:3633–3639. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu N, et al: Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci. 99:280–286. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang D, Xiao YF, Zhang JW, Xie R, Hu CJ, Tang B, Wang SM, Wu YY, Hao NB and Yang SM: miR-1182 attenuates gastric cancer proliferation and metastasis by targeting the open reading frame of hTERT. Cancer Lett. 360:151–159. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Melnik BC: miR-21: An environmental driver of malignant melanoma? J Transl Med. 13:2022015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Yang JJ, Tao H and Jin WS: MicroRNA-21 controls hTERT via PTEN in human colorectal cancer cell proliferation. J Physiol Biochem. 71:59–68. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen DD and Chang S: Development of novel therapeutic agents by inhibition of oncogenic microRNAs. Int J Mol Sci. 19(pii): E652017. View Article : Google Scholar : PubMed/NCBI | |
|
Mizukoshi E and Kaneko S: Telomerase-targeted cancer immunotherapy. Int J Mol Sci. 20(pii): E18232019. View Article : Google Scholar : PubMed/NCBI | |
|
Staff C, Mozaffari F, Frödin JE, Mellstedt H and Liljefors M: Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. Int J Oncol. 45:1293–1303. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G, et al: A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother. 62:1041–1052. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fenoglio D, Parodi A, Lavieri R, Kalli F, Ferrera F, Tagliamacco A, Guastalla A, Lamperti MG, Giacomini M and Filaci G: Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one. Hum Vaccin Immunother. 11:838–850. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH and Inderberg EM: Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunol Immunother. 66:891–901. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis D and Georgoulias V: A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer. 86:59–66. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E and Vieweg J: Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 174:3798–3807. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Khoury HJ, Collins RH Jr, Blum W, Stiff PS, Elias L, Lebkowski JS, Reddy A, Nishimoto KP, Sen D, Wirth ED III, et al: Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer. 123:3061–3072. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Galati D and Zanotta S: Empowering dendritic cell cancer vaccination: The role of combinatorial strategies. Cytotherapy. 20:1309–1323. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Salazar-Onfray F, Pereda C, Reyes D and López MN: TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer. Biol Res. 46:431–440. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Thalmensi J, Pliquet E, Liard C, Escande M, Bestetti T, Julithe M, Kostrzak A, Pailhes-Jimenez AS, Bourges E, Loustau M, et al: Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Oncoimmunology. 5:e10836702016. View Article : Google Scholar : PubMed/NCBI | |
|
Yan J, Pankhong P, Shin TH, Obeng-Adjei N, Morrow MP, Walters JN, Khan AS, Sardesai NY and Weiner DB: Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res. 1:179–189. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ohta R, Demachi-Okamura A, Akatsuka Y, Fujiwara H and Kuzushima K: Improving TCR affinity on 293T cells. J Immunol Methods. 466:1–8. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jordheim LP, Durantel D, Zoulim F and Dumontet C: Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 12:447–464. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K and Schnapp A: Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem. 277:15566–15572. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MY, Vankayalapati H, Shin-Ya K, Wierzba K and Hurley LH: Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc. 124:2098–2099. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gomez DL, Armando RG, Cerrudo CS, Ghiringhelli PD and Gomez DE: Telomerase as a cancer target. Development of new molecules. Curr Top Med Chem. 16:2432–2440. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, et al: A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 18:429–434. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Chen P, Marais R and Springer CJ: Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res. 67:4949–4955. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Picard D: Intracellular dynamics of the Hsp90 co-chaperone p23 is dictated by Hsp90. Exp Cell Res. 312:198–204. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ning X, Yang S, Wang R, Zhang R, Guo L, Tie J, Cheng Y, Wang G, Wan S and Fang D: POT1 deficiency alters telomere length and telomere-associated gene expression in human gastric cancer cells. Eur J Cancer Prev. 19:345–351. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ganesan K and Xu B: Telomerase inhibitors from natural products and their anticancer potential. Int J Mol Sci. 19(pii): E132017. View Article : Google Scholar : PubMed/NCBI | |
|
Mizushina Y, Takeuchi T, Sugawara F and Yoshida H: Anti-cancer targeting telomerase inhibitors: β-rubromycin and oleic acid. Mini Rev Med Chem. 12:1135–1143. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Smith S: Telomerase can't handle the stress. Genes Dev. 32:597–599. 2018. View Article : Google Scholar : PubMed/NCBI |
